Agios Pharmaceuticals, Inc. (AGIO)
32.60
-0.49
(-1.48%)
USD |
NASDAQ |
Aug 24, 16:00
32.33
-0.27
(-0.83%)
After-Hours: 20:00
Agios Pharmaceuticals EPS Diluted (Quarterly) : -1.693 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.693 |
| March 31, 2026 | -1.686 |
| December 31, 2025 | -1.852 |
| September 30, 2025 | -1.779 |
| June 30, 2025 | -1.934 |
| March 31, 2025 | -1.554 |
| December 31, 2024 | -1.689 |
| September 30, 2024 | 16.22 |
| June 30, 2024 | -1.692 |
| March 31, 2024 | -1.446 |
| December 31, 2023 | -1.716 |
| September 30, 2023 | -1.636 |
| June 30, 2023 | -1.507 |
| March 31, 2023 | -1.466 |
| December 31, 2022 | 0.6636 |
| September 30, 2022 | -1.490 |
| June 30, 2022 | -1.675 |
| March 31, 2022 | -1.737 |
| December 31, 2021 | -1.742 |
| September 30, 2021 | -1.545 |
| June 30, 2021 | -1.366 |
| March 31, 2021 | -1.70 |
| December 31, 2020 | -1.410 |
| September 30, 2020 | -1.432 |
| June 30, 2020 | -1.312 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.5868 |
| December 31, 2019 | -1.600 |
| September 30, 2019 | -1.806 |
| June 30, 2019 | -1.871 |
| March 31, 2019 | -1.592 |
| December 31, 2018 | -1.578 |
| September 30, 2018 | -1.631 |
| June 30, 2018 | -1.191 |
| March 31, 2018 | -1.631 |
| December 31, 2017 | -1.81 |
| September 30, 2017 | -1.59 |
| June 30, 2017 | -1.78 |
| March 31, 2017 | -1.56 |
| December 31, 2016 | -1.34 |
| September 30, 2016 | -1.63 |
| June 30, 2016 | -1.47 |
| March 31, 2016 | -0.61 |
| December 31, 2015 | -1.08 |
| September 30, 2015 | -1.07 |
| June 30, 2015 | -0.85 |
| March 31, 2015 | -0.13 |
| December 31, 2014 | -0.76 |
| September 30, 2014 | 0.10 |
| June 30, 2014 | -0.54 |
| March 31, 2014 | -0.39 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Biogen, Inc. | 0.6557 |
| Insmed, Inc. | -0.0609 |
| Liquidia Corp. | 0.7369 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -100.70M |
| Revenue (Quarterly) | 44.74M |
| Total Expenses (Quarterly) | 145.45M |
| Enterprise Value | 1.386B |
| Gross Profit Margin (Quarterly) | 90.29% |
| Profit Margin (Quarterly) | -225.1% |
| Earnings Yield | -21.50% |
| Normalized Earnings Yield | -21.50 |